Is adaptive Biotechnologies a bullish stock?

The public market is bullish on Adaptive Biotechnologies. The biotech company started trading on the Nasdaq exchange under the symbol ADPT at $38 per share Thursday morning, up 90 percent from the $20 per share price it set Wednesday evening after raising $300 million its IPO.

Is adaptive Biotechnologies a good stock to buy?

According to analysts, Adaptive Biotechnologies's stock has a predicted upside of 58.34% based on their 12-month price targets. What analysts cover Adaptive Biotechnologies?

What is adaptive Biotechnologies Corporation?

Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-cell and B-cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer.